UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its pipeline ahead of a key patent expiry, as US hedge fund Citadel took the largest short position ...

Women in England with a specific type of endometrial cancer will be able to access an immunotherapy for the first time, after NICE backed use of GlaxoSmithKline's PD-1 inhibitor Jemperli via the ...

The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions for the ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

Also in Europe, officials have endorsed GSK's Jemperli to treat all adult patients with primary advanced or recurrent endometrial cancer, including those with mismatch repair proficient (MMRp ...

Uterine cancer (also known as endometrial cancer) is the fourth most common cancer women in the U.S. are diagnosed with. It ...

The majority of women with uterine fibroids are asymptomatic, consequently get less clinical attention and fibroid tumors often remain undiagnosed. [23,24] Symptomatic women typically complain ...

Reproductive tract problems—Uterine fibroids and polyps (growths) or infections are common causes of abnormal bleeding. Precancer or cancer in the uterus, cervix (opening of the uterus), or ...

Colon cancer develops when tumorous growths form in the large intestine. It often produces no symptoms in the early stages, but people should see a doctor if they notice persistent changes in ...

Feb. 19, 2025 — Clinical research suggests that combining a novel agent called navtemadlin with DNA-damaging chemotherapy for the treatment of glioblastoma, a form of brain cancer, could ...

Highlights Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%).Second quarter GAAP earnings per share ...